Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).

Patel TA, Ensor JE, Creamer SL, Boone T, Rodriguez AA, Niravath PA, Darcourt JG, Meisel JL, Li X, Zhao J, Kuhn JG, Rosato RR, Qian W, Belcheva A, Schwartz MR, Kaklamani VG, Chang JC.

Breast Cancer Res. 2019 Sep 2;21(1):100. doi: 10.1186/s13058-019-1186-0.

2.

EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.

Bardia A, Aftimos P, Bihani T, Anderson-Villaluz AT, Jung J, Conlan MG, Kaklamani VG.

Future Oncol. 2019 Aug 20. doi: 10.2217/fon-2019-0370. [Epub ahead of print]

3.

Developing a model to predict accrual to cancer clinical trials: Data from an NCI designated cancer center.

Iruku P, Goros M, Gelfond J, Chang J, Padalecki S, Mesa R, Kaklamani VG.

Contemp Clin Trials Commun. 2019 Jul 19;15:100421. doi: 10.1016/j.conctc.2019.100421. eCollection 2019 Sep.

4.

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3.

PMID:
31157962
5.

Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer.

Kaklamani VG, Richardson AL, Arteaga CL.

Oncologist. 2019 Mar;24(3):305-312. doi: 10.1634/theoncologist.2018-0314. Epub 2019 Jan 16. Review.

PMID:
30651399
6.

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3.

7.

Multi-gene Panel Testing in Breast Cancer Management.

Fountzilas C, Kaklamani VG.

Cancer Treat Res. 2018;173:121-140. doi: 10.1007/978-3-319-70197-4_8. Review.

PMID:
29349761
8.

Developments in Breast Cancer 2017-2018: New Drugs, New Drug Classes-and the Prospect of More to Come.

Kaklamani VG.

Oncology (Williston Park). 2017 Dec 15;31(12 Suppl 1):6-7. No abstract available.

9.

Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.

Wu Y, Zhang Z, Cenciarini ME, Proietti CJ, Amasino M, Hong T, Yang M, Liao Y, Chiang HC, Kaklamani VG, Jeselsohn R, Vadlamudi RK, Huang TH, Li R, De Angelis C, Fu X, Elizalde PV, Schiff R, Brown M, Xu K.

Cancer Res. 2018 Feb 1;78(3):671-684. doi: 10.1158/0008-5472.CAN-17-1327. Epub 2017 Dec 6.

10.

Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer.

Rao SS, Stoehr J, Dokic D, Wan L, Decker JT, Konopka K, Thomas AL, Wu J, Kaklamani VG, Shea LD, Jeruss JS.

Oncotarget. 2017 Aug 10;8(48):83925-83939. doi: 10.18632/oncotarget.20202. eCollection 2017 Oct 13.

11.

A pilot study of cabergoline for the treatment of metastatic breast cancer.

Costa R, Santa-Maria CA, Scholtens DM, Jain S, Flaum L, Gradishar WJ, Clevenger CV, Kaklamani VG.

Breast Cancer Res Treat. 2017 Oct;165(3):585-592. doi: 10.1007/s10549-017-4370-x. Epub 2017 Jul 3.

PMID:
28674764
12.

Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer.

Kaklamani VG, Gradishar WJ.

Oncologist. 2017 May;22(5):507-517. doi: 10.1634/theoncologist.2015-0464. Epub 2017 Mar 17. Review.

13.

A prospective evaluation of clinical and genetic predictors of weight changes in breast cancer survivors.

Sadim M, Xu Y, Selig K, Paulus J, Uthe R, Agarwl S, Dubin I, Oikonomopoulou P, Zaichenko L, McCandlish SA, Van Horn L, Mantzoros C, Ankerst DP, Kaklamani VG.

Cancer. 2017 Jul 1;123(13):2413-2421. doi: 10.1002/cncr.30628. Epub 2017 Feb 14.

14.

Correlating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods.

Patel TA, Puppala M, Ogunti RO, Ensor JE, He T, Shewale JB, Ankerst DP, Kaklamani VG, Rodriguez AA, Wong ST, Chang JC.

Cancer. 2017 Jan 1;123(1):114-121. doi: 10.1002/cncr.30245. Epub 2016 Aug 29.

15.

Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer.

Kaklamani VG.

Oncologist. 2016 Aug;21(8):922-30. doi: 10.1634/theoncologist.2015-0366. Epub 2016 Jun 2. Review.

16.

Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer?

Kaklamani VG, Gradishar WJ.

J Natl Compr Canc Netw. 2015 Nov;13(11):1448-52. No abstract available.

PMID:
26553770
17.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW.

N Engl J Med. 2015 Nov 19;373(21):2005-14. doi: 10.1056/NEJMoa1510764. Epub 2015 Sep 27.

18.

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).

Kaklamani VG, Jeruss JS, Hughes E, Siziopikou K, Timms KM, Gutin A, Abkevich V, Sangale Z, Solimeno C, Brown KL, Jones J, Hartman AR, Meservey C, Jovanovic B, Helenowski I, Khan SA, Bethke K, Hansen N, Uthe R, Giordano S, Rosen S, Hoskins K, Von Roenn J, Jain S, Parini V, Gradishar W.

Breast Cancer Res Treat. 2015 Jun;151(3):629-38. doi: 10.1007/s10549-015-3435-y. Epub 2015 May 26.

PMID:
26006067
19.

Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.

Gordon AC, Gradishar WJ, Kaklamani VG, Thuluvath AJ, Ryu RK, Sato KT, Gates VL, Salem R, Lewandowski RJ.

J Vasc Interv Radiol. 2014 Oct;25(10):1523-32, 1532.e1-2. doi: 10.1016/j.jvir.2014.07.007. Epub 2014 Aug 22.

20.

Predicting benefit from imatinib: are we close?

Gandhi MD, Kaklamani VG.

Leuk Lymphoma. 2014 Nov;55(11):2421-2. doi: 10.3109/10428194.2014.909041. Epub 2014 Apr 22. No abstract available.

PMID:
24684225
21.

Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.

Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG; Northwestern Cancer Genetics Group.

Cancer. 2014 May 15;120(10):1557-64. doi: 10.1002/cncr.28577. Epub 2014 Feb 12.

22.

Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer.

Reddy SM, Sadim M, Li J, Yi N, Agarwal S, Mantzoros CS, Kaklamani VG.

Br J Cancer. 2013 Aug 20;109(4):872-81. doi: 10.1038/bjc.2013.441. Epub 2013 Aug 6.

23.

Adiponectin pathway polymorphisms and risk of breast cancer in African Americans and Hispanics in the Women's Health Initiative.

Kaklamani VG, Hoffmann TJ, Thornton TA, Hayes G, Chlebowski R, Van Horn L, Mantzoros C.

Breast Cancer Res Treat. 2013 Jun;139(2):461-8. doi: 10.1007/s10549-013-2546-6. Epub 2013 Apr 30.

24.

The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies.

Economopoulou P, Kaklamani VG, Siziopikou K.

Oncologist. 2012;17(11):1394-401. doi: 10.1634/theoncologist.2012-0163. Epub 2012 Aug 31. Review.

25.

Diabetes, metformin, and breast cancer in postmenopausal women.

Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T, Ipp E, Kaklamani VG, Vitolins M, Wallace R, Gunter M, Phillips LS, Strickler H, Margolis K, Euhus DM.

J Clin Oncol. 2012 Aug 10;30(23):2844-52. doi: 10.1200/JCO.2011.39.7505. Epub 2012 Jun 11.

26.

Metabolic syndrome and triple-negative breast cancer: a new paradigm.

Davis AA, Kaklamani VG.

Int J Breast Cancer. 2012;2012:809291. doi: 10.1155/2012/809291. Epub 2011 Oct 15.

27.

Global experience with ixabepilone in breast cancer.

Kaklamani VG, Xu BH, Gomez HL.

Expert Rev Anticancer Ther. 2011 May;11(5):683-92. doi: 10.1586/era.11.41. Review.

PMID:
21554041
28.

Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.

Kaklamani VG, Siziopikou K, Scholtens D, Lacouture M, Gordon J, Uthe R, Meservey C, Hansen N, Khan SA, Jeruss JS, Bethke K, Cianfrocca M, Rosen S, Von Roenn J, Wayne J, Parimi V, Jovanovic B, Gradishar W.

Breast Cancer Res Treat. 2012 Apr;132(3):833-42. doi: 10.1007/s10549-011-1411-8. Epub 2011 Feb 27.

PMID:
21359953
29.

Bayesian analysis of genetic interactions in case-control studies, with application to adiponectin genes and colorectal cancer risk.

Yi N, Kaklamani VG, Pasche B.

Ann Hum Genet. 2011 Jan;75(1):90-104. doi: 10.1111/j.1469-1809.2010.00605.x. Epub 2010 Sep 15.

30.

Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease.

Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, Le JM, Yang B, Korman BD, Cakiris A, Aglar O, Emrence Z, Azakli H, Ustek D, Tugal-Tutkun I, Akman-Demir G, Chen W, Amos CI, Dizon MB, Kose AA, Azizlerli G, Erer B, Brand OJ, Kaklamani VG, Kaklamanis P, Ben-Chetrit E, Stanford M, Fortune F, Ghabra M, Ollier WE, Cho YH, Bang D, O'Shea J, Wallace GR, Gadina M, Kastner DL, Gül A.

Nat Genet. 2010 Aug;42(8):698-702. doi: 10.1038/ng.625. Epub 2010 Jul 11.

31.

Increased HER2/neu expression in recurrent hormone receptor-positive breast cancer.

Kaklamani VG, Cianfrocca M, Ciccone J, Kindy K, Rademaker A, Wiley EL, Gradishar W, O'Regan RM.

Biomarkers. 2010 Mar;15(2):191-3. doi: 10.3109/13547500903312173. No abstract available.

PMID:
19839717
32.

Role of polymorphisms in Adamantiades-Behçet's disease.

Kaklamani VG, Sadim M, Koumantaki Y, Kaklamanis P, Pasche B.

J Rheumatol. 2008 Dec;35(12):2376-8. Epub 2008 Oct 15.

33.

Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk.

Kaklamani VG, Wisinski KB, Sadim M, Gulden C, Do A, Offit K, Baron JA, Ahsan H, Mantzoros C, Pasche B.

JAMA. 2008 Oct 1;300(13):1523-31. doi: 10.1001/jama.300.13.1523.

34.

Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk.

Kaklamani VG, Sadim M, Hsi A, Offit K, Oddoux C, Ostrer H, Ahsan H, Pasche B, Mantzoros C.

Cancer Res. 2008 May 1;68(9):3178-84. doi: 10.1158/0008-5472.CAN-08-0533.

35.

HER2-positive breast cancer: current and future treatment strategies.

Engel RH, Kaklamani VG.

Drugs. 2007;67(9):1329-41. Review.

PMID:
17547474
36.

Role of efaproxiral in metastatic brain tumors.

Engel RH, Kaklamani VG.

Expert Rev Anticancer Ther. 2006 Apr;6(4):477-85. Review.

PMID:
16613536
37.

Gene expression in breast cancer.

Kaklamani VG, Gradishar WJ.

Curr Treat Options Oncol. 2006 Mar;7(2):123-8. Review.

PMID:
16455023
38.

Behçet's disease associated with malignancies. Report of two cases and review of the literature.

Kaklamani VG, Tzonou A, Kaklamanis PG.

Clin Exp Rheumatol. 2005 Jul-Aug;23(4 Suppl 38):S35-41. Review.

PMID:
16273762
39.

Adjuvant therapy of breast cancer.

Kaklamani VG, Gradishar WJ.

Minerva Ginecol. 2005 Oct;57(5):521-36. Review.

PMID:
16205597
40.

Adjuvant therapy of breast cancer.

Kaklamani VG, Gradishar WJ.

Cancer Invest. 2005;23(6):548-60. Review.

PMID:
16203663
41.

Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk.

Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C, Hegarty C, McDaniel B, Rademaker A, Oddoux C, Ostrer H, Michel LS, Huang H, Chen Y, Ahsan H, Offit K, Pasche B.

Cancer Res. 2005 Apr 15;65(8):3454-61. Erratum in: Cancer Res. 2006 Mar 15;66(6):3345.

42.

The assessment and management of cancer treatment-related diarrhea.

O'Brien BE, Kaklamani VG, Benson AB 3rd.

Clin Colorectal Cancer. 2005 Mar;4(6):375-81; discussion 382-3. Review.

PMID:
15807929
43.

Adjuvant therapy of breast cancer in the elderly: does one size fit all?

Gradishar WJ, Kaklamani VG.

JAMA. 2005 Mar 2;293(9):1118-20. No abstract available.

PMID:
15741536
44.

Role of TGF-beta in cancer and the potential for therapy and prevention.

Kaklamani VG, Pasche B.

Expert Rev Anticancer Ther. 2004 Aug;4(4):649-61. Review.

PMID:
15270668
45.

TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies.

Kaklamani VG, Hou N, Bian Y, Reich J, Offit K, Michel LS, Rubinstein WS, Rademaker A, Pasche B.

J Clin Oncol. 2003 Sep 1;21(17):3236-43.

PMID:
12947057
46.

The effect of smoking on the clinical features of Adamantiades-Behçet's disease.

Kaklamani VG, Tzonou A, Markomichelakis N, Papazoglou S, Kaklamanis PG.

Adv Exp Med Biol. 2003;528:323-7. No abstract available.

PMID:
12918715
47.

Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?

Kaklamani VG, Gradishar WJ.

Clin Breast Cancer. 2003 Apr;4 Suppl 1:S26-33. Review.

PMID:
12756076
48.

Role of capecitabine (Xeloda) in breast cancer.

Kaklamani VG, Gradishar WJ.

Expert Rev Anticancer Ther. 2003 Apr;3(2):137-44. Review.

PMID:
12722873
49.

Advances in adjuvant chemotherapy for breast cancer: the role of taxanes.

Kaklamani VG, Gradishar WJ.

J Natl Compr Canc Netw. 2003 Jan;1 Suppl 1:S107-18. Review.

PMID:
19795584
50.

Could nicotine be beneficial for Behçet's disease?

Kaklamani VG, Markomichelakis N, Kaklamanis PG.

Clin Rheumatol. 2002 Aug;21(4):341-2. No abstract available.

PMID:
12296287

Supplemental Content

Loading ...
Support Center